SAB Biotherapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company developing SAB-142 for type 1 diabetes and other autoimmune diseases. Form 8-K disclosures cover clinical presentations, Regulation FD materials, and material agreements, including manufacturing services for SAB-142.
The company’s filings also describe its capital structure and financing activity, including common stock, pre-funded warrants, public offering agreements and shelf registration use. Proxy materials cover annual meeting matters, director elections, board composition, stockholder voting items and related governance disclosures.
SAB Biotherapeutics insider conversion increases public float via Sessa Capital. The filing reports that Series B Convertible Preferred Stock held by Sessa Capital (Master), L.P. automatically converted into 1,740,000 common shares at an effective conversion price of $1.75 per underlying share, reflecting conversion of 17,400 preferred shares. After the conversion the Sessa Parties are reported to beneficially own 2,198,457 common shares in aggregate, held indirectly through related entities.
The Preferred Stock was purchased by the Fund for an aggregate price of $39,987,500 under a July 21, 2025 purchase agreement. The filing discloses a 4.99% beneficial ownership cap that limits further conversions that would push the Sessa Parties above that threshold. Andrew Moin is identified as a board director of the issuer and is an Analyst and Partner with the Fund; the reported holdings are described as indirect and subject to the stated ownership limitation.
Sessa Capital reported the automatic conversion of Series B Convertible Preferred Stock into common stock of SAB Biotherapeutics (SABS) on 09/29/2025. The filing shows the Fund received 1,740,000 common shares as a result of converting 17,400 preferred shares at an effective price of $1.75 per share. The Fund originally acquired the preferred shares for an aggregate purchase price of $39,987,500 under a July 21, 2025 purchase agreement. After the conversion, the reporting persons collectively beneficially owned 2,198,457 shares of common stock. The conversion is subject to a 4.99% beneficial ownership limitation that restricts further conversions that would exceed that threshold.
SAB Biotherapeutics, Inc. reported that on September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned from its Board of Directors. Their departures were made in line with a letter agreement between the company and RA Capital Healthcare Fund, L.P. related to a July 2025 private placement of securities. Following these resignations, the Board size was reduced from 11 to nine members. The company stated that the resignations were not due to any disagreement regarding its operations, policies, or practices and expressed appreciation for both directors’ service.
SAB Biotherapeutics, Inc. stockholders approved two major equity-related proposals at a special meeting. First, they approved the potential issuance of more than 19.99% of the company’s outstanding common stock upon conversion of its Series B Convertible Preferred Stock at less than the Nasdaq “minimum price,” a step that may be deemed a change of control under Nasdaq rules.
Second, stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan that increases the share pool for awards by 24,180,000 shares to an aggregate of 31,932,466 shares and raises the maximum annual “evergreen” increase from 10,000,000 shares to 73,750,000 shares. The Plan amendment passed with 5,089,862 votes for and 951,598 against, while the Series B conversion proposal passed with 5,502,026 votes for and 515,275 against.
SAB Biotherapeutics describes clinical and corporate disclosures in this amended shelf filing. The filing reports that SAB-142 showed a favorable safety profile in Phase 1 across a dose range of 0.03 mg/kg to 2.5 mg/kg, with 0% reported serum sickness and 0% reported anti-drug antibodies, supporting chronic ambulatory dosing. The company states SAB-142 demonstrated sustained immunomodulation and a multi-target mechanism of action analogous to rabbit ATG on parameters correlative to C-peptide preservation.
The prospectus reiterates extensive risk-factor topics and lists permitted methods for secondary distributions by selling stockholders. It also references recent SEC filings, including the 2024 annual report and quarterly and current reports filed in 2025, without providing financial results in the included excerpt.
Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (ticker: SABSW), reported a routine insider transaction dated 09/19/2025. The Form 4 shows 1,977 shares of common stock were disposed through withholding to satisfy tax obligations on vested restricted stock units (RSUs). Following the transaction, she beneficially owns 45,272 shares, which include 29,340 vested shares and 15,932 RSUs that remain subject to vesting.
The filing is a standard Section 16 disclosure reflecting tax-withholding on RSU vesting rather than an open-market sale or purchase. The form was signed by Ms. Kropotova on 09/22/2025 and does not disclose any derivative transactions or other changes in ownership form.